A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Despite regulatory hurdles, Cronos Group Inc (CRON) posts record net revenue and gross profit, driven by strong Canadian brand performance and international momentum.

Cronos Group Inc. has reported its second-quarter 2026 results, with sales rising to US$70.6 million and revenue to US$53.01 million, alongside a shift from a net loss to net income of US$32.09 million compared with the same period last year. This move into profitability, with basic earnings per share from continuing operations at US$0.09 versus a loss per share a year earlier, highlights a clear improvement in operating performance over both the quarter and first half of 2026. We’ll now...

Cronos Group (NASDAQ:CRON) reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany. Consolidated net revenue rose 58% year over year to $53 million, while gross profit increased 9

Cronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?